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doi:10.1Background:We performed the first human case of successful transapical transcatheter aortic valve implantation
on a beating heart in October 2005, and therefore we have the longest follow-up on transapical aortic valve
implantation in humans. We now report clinical and echocardiographic outcomes of transapical aortic valve
implantation in 71 patients.
Methods: Between October 2005 and February 2009, 71 patients (44 female) underwent transcatheter trans-
apical aortic valve implantation with either 23- or 26-mm Edwards Lifesciences transcatheter bioprostheses.
All patients with symptomatic aortic stenosis were declined for conventional aortic valve replacement owing
to unacceptable operative risks and were not candidates for transfemoral aortic valve implantation because
of poor arterial access. Clinical and echocardiographic follow-ups were performed before discharge, at 1
and 6 months, and then yearly. The mean follow-up was 12.9  11.5 months with a total of 917.3 months
of follow-up.
Results:Mean age was 80.0 8.1 years and predicted operative mortality was 34.5% 20.4% by logistic Euro-
SCORE and 12.1%  7.7% by The Society of Thoracic Surgeons Risk Calculator. Valves were successfully
implanted in all patients. Twelve patients died within 30 days (30-day mortality: 16.9% in all patients, 33%
in the first 15 patients, and 12.5% in the remainder), and 10 patients died subsequently. Overall survival at 24
and 36 months was 66.3%  6.4% and 58.0%  9.5%, respectively. Among 59 patients who survived at least
30 days, 24- and 36-month survivals were 79.8% 6.4% and 69.8% 10.9%, respectively. Late valve-related
complications were rare. New York Heart Association functional class improved significantly from preoperative
3.3  0.8 to 1.8  0.8 at 24 months. The aortic valve area and mean gradient remained stable at 24 months
(1.6  0.3 cm2 and 10.3  5.9 mm Hg, respectively).
Conclusion: Our outcome suggests that transapical transcatheter aortic valve implantation provides sustained
clinical and hemodynamic benefits for up to 36 months in selected high-risk patients with symptomatic severe
aortic stenosis. (J Thorac Cardiovasc Surg 2010;139:1107-13)Supplemental material is available online.Aortic valve replacement (AVR) with cardiopulmonary
bypass (CPB) has been the only treatment that offers both
symptomatic relief and the potential for improved long-
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The Journal of Thoracic and Carpatients with symptomatic severe degenerative aortic
stenosis.1 However, inasmuch as a considerable number of
elderly patients with symptomatic severe aortic stenosis
have significant comorbidities, open heart AVR with CPB
can be associated with an unacceptable perioperative mortal-
ity and morbidity in this group. Over the past 5 years, the
development of minimally invasive transcatheter valve
implantation has been explored.2-13 Transarterial and trans-
apical transcatheter aortic valve implantation (AVI) has been
explored by cardiologists and cardiac surgeons worldwide.
Many reports have shown favorable early clinical and
echocardiographic outcomes with transarterial or transapical
AVI. We reported the first successful transcatheter transap-
ical AVI through a left minithoracotomy and the apex of
the left ventricle without CPB in humans,11,12 followed by
our early clinical experience with transapical transcatheter
AVI without CPB.14-16 Our early experience and that of
others17 have shown that transapical transcatheter AVI
definitely relieves aortic stenosis and significantly improves
valve-related symptoms. We now report clinical and echo-
cardiographic outcomes of transapical AVI in our first
71 patients.diovascular Surgery c Volume 139, Number 5 1107
Abbreviations and Acronyms
AVI ¼ aortic valve implantation
AVR ¼ aortic valve replacement
CPB ¼ cardiopulmonary bypass
NYHA ¼ New York Heart Association
STS ¼ The Society of Thoracic Surgeons
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DMETHODS
The transapical procedure was approved by the Therapeutic Products
Directorate, Department of Health and Welfare, Ottawa, Canada, for com-
passionate clinical use in patients with symptomatic severe aortic stenosis
deemed not to be candidates for routine open heart AVR and unsuitable
for percutaneous transfemoral AVI.
Patient Selection
All patients were assessed independently by at least two cardiologists
and two cardiac surgeons. Theywere accepted for the procedure on the basis
of the consensus that conventional surgery was an excessively high risk in
terms of anticipatedmortality andmorbidity. Patient or physician preference
alone was not considered adequate. Therefore, this cohort of patients was
usually elderly and frail with multiple comorbidities. Porcelain aorta was
the most common single reason for declining conventional AVR. Currently,
there is no single risk calculator that can accurately estimate operative risk in
the elderly. EuroSCORE and The Society of Thoracic Surgeons (STS) score
were not used to determine the fitness for open heart AVR.Written informed
consent was obtained.
Transapical AVI was recommended if aortofemoral angiography and/or
computed tomographic angiography revealed aortic and/or iliofemoral arte-
rial anatomy unfavorable for the transfemoral approach, such as the dimen-
sion of iliofemoral arteries of less than 7.0 mm for the 23-mm valve and less
than 8 mm for the 26-mm valve if the RetroFlex 3 delivery system (Edwards
Lifesciences, Irvine, Calif) was used or less than 6.5 mm if the NovaFlex
delivery system (Edwards)was considered. The characteristics of 71 patients
are listed in Table E1.
Prosthetic Valve Implantation
The procedure of transapical transcatheter AVI was described in detail in
our previous publications.11,14,15 All patients including our first patient
underwent transapical AVI on the beating heart through an approximately
5-cm anterolateral minithoracotomy in an operating room.
Heparin was administered to achieve an activated clotting time of 300
seconds or more. With the use of fluoroscopic, aortographic, and transeso-
phageal echocardiographic imaging, balloon valvuloplasty and then deploy-
ment of the bioprosthesis were performed during rapid ventricular pacing to
minimize ventricular ejection. Cribier–Edwards transcatheter equine peri-
cardial tissue valves (Edwards) were used in the first 8 patients and SAPIEN
THV bovine pericardial tissue valves (Edwards) in subsequent patients.
Either 23-mm or 26-mm transcatheter tissue valves were used. Patients
were maintained on aspirin indefinitely and on clopidogrel for 3 months.
Warfarin was routinely used in 8 patients in our early series, of whom
2 patients had gastrointestinal bleeding within 30 days. Therefore, we
stopped routine use of warfarin unless there were other indications, such
as atrial fibrillation or an existing mechanical valve.
Follow-up and Data Collection
All patients were carefully followed up by cardiac surgeons, cardiolo-
gists, clinical fellows, and clinical research coordinators. Clinical follow-
up and echocardiography were obtained before discharge (69 patients)
and at 1 (51 patients), 6 (42 patients), 12 (35 patients), 24 (17 patients),1108 The Journal of Thoracic and Cardiovascular Surand 36 (4 patients) months. The mean follow-up was 12.9  11.5 months,
with a total of 917.3 months. The longest follow-up was 37.3 months. Every
patient (including our first patient) who underwent transapical isolated AVI
is included in the report. Data are presented as mean  standard deviation.
One-way analysis of variance with generalized linear model was used to
compare echocardiographic parameters (aortic valve area, mean transaortic
pressure gradient, aortic insufficiency, left ventricular ejection fraction, and
mitral regurgitation) and New York Heart Association (NYHA) class
between different time points. Multiple comparisons among the different
time points were performed using the least significant difference post hoc
test. Bonferroni correction was used to evaluate the significance of the mul-
tiple comparisons. The Kaplan–Meier method was used to generate survival
curves. The statistical analyses were performed with the SAS (version 9.1.3)
statistical software package (SAS Institute, Inc, Cary, NC).
RESULTS
Patients
Mean age of 71 patients (44 female) was 80.0 8.1 years.
Predicted operative mortality was 34.5% 20.4% by logis-
tic EuroSCORE and 12.1% 7.7% by the STS Risk Calcu-
lator. Seventeen patients were not accepted for conventional
AVR despite low estimates of operative mortality (STS
score<10%) because of porcelain ascending aorta, severe
lung disease, or end-stage liver cirrhosis.
Intraoperative Outcome
Transapical transcatheter AVI via a left anterior minithor-
acotomy without CPB was successfully performed in all
71 patients. Bioprostheses were 23 mm in diameter in
28 patients and 26 mm in 43 patients. In 2 patients a second
transcatheter bioprosthesis was implanted for significant
paravalvular leaks owing to suboptimal positioning of the
first transcatheter bioprosthesis. One patient died immedi-
ately after completion of the procedure in the operating
room, probably as a result of obstruction of the left coronary
ostium by a native bulky calcified aortic valve. This patient
also had significant intraoperative bleeding owing to diffi-
cult hemostasis at the puncture site of the left ventricular
apex. A second patient had cardiac arrest at the time when
minithoracotomy was performed and died of heart failure
despite subsequent successful AVI with the support of
femorofemoral CPB. Another patient had a perforation
of a severely calcified aortic root after deployment of the
transcatheter valve, for which emergency open heart aortic
root replacement was done.
Early Clinical Outcome
Of the 71 patients, 12 patients died within 30 days after
AVI. Of the 12 deaths, 2 occurred intraoperatively. The
overall 30-day mortality was 16.9%. In the initial 15 pa-
tients there were 5 deaths for an early mortality of 33%.
After this initial learning curve, 7 of the remaining
56 patients died for an early mortality of 12.5%. Predicted
operative mortality by STS Risk Calculator and Euro-
SCORE were similar for the first 15 cases and the subse-
quent 56 cases (Table 1). The causes of postoperativegery c May 2010
TABLE 1. Predicted and observed 30-day mortality
All 71 cases First 15 cases
Remaining
56 cases
Predicted mortality (%)
Logistic EuroSCORE 34.5  20.4 31.0  20.0 36.0  20.8
STS Score 12.1  7.7 10.0  6.0 12.7  8.1
Observed mortality (%) 16.9 33.3 12.5
Age (y) 80.0  9.0 78.0  11.0 80.0  7.2
STS, The Society of Thoracic Surgeons.
FIGURE 1. Kaplan–Meier survival in 71 patients. SE, Standard error.
FIGURE 2. Kaplan–Meier survival in 59 patients who survived at least 30
days. SE, Standard error.
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D10 deaths included pneumonia (2 patients), ischemic bowel
(2 patients), vascular complication/ischemic leg (2 patients),
pulmonary embolism (1 patient), multiple organ failure
(2 patients), and massive hemorrhage from chest tube rein-
sertion in a patient with existing liver failure and coagulop-
athy (1 patient). Six (8.5%) patients required new
pacemaker implantation within 30 days after the procedure,
of whom 2 patients had sick sinus syndrome, and 4 (5.6%)
patients had heart block. One patient’s course was compli-
cated by cerebrovascular accident (1.4%).
Late Clinical Outcomes
Of 59 patients surviving more than 30 days, 10 patients
died of non–valve-related complications. The causes of the
deaths include cancer (1 patient), lung diseases (severe
chronic obstructive pulmonary disease and/or pneumonia/
sepsis in 4 patients), myocardial infarction (1 patient), mul-
tiple organ failure (congestive heart failure, severe chronic
renal failure, and chronic obstructive pulmonary disease in
2 patients), gastrointestinal bleeding (1 patient), and multi-
ple factors/organ failure (cachexia and anorexia in 1 patient).
Late valve-related complications were very uncommon.
There was no valve thrombosis, endocarditis, or structural
valve deterioration. Overall survival at 24 and 36 months
was 66.3%  6.4% and 58.0%  9.5%, respectively.
Among patients (59 patients) who survived at least 30
days, 24- and 36-month survivals were 79.8%  6.4%
and 69.8%  10.9%, respectively. If the first 15 patients
were excluded as an initial learning curve, 24-month
survival in 56 patients was 68.1%  7.9%. Figures 1 to 3
illustrate the Kaplan–Meier survival after transapical trans-
catheter AVI.
The majority of the patients (86.2%) had NYHA class III
and IV heart failure symptoms before the procedure.
Remarkable improvement in functional class was observed
after transapical AVI, and 83.9% and 75% patients had
NYHA class I or II heart failure symptoms at 12 and 24
months’ follow-up, respectively. Mean NYHA class
decreased from 3.3  0.8 preoperatively to 1.7  0.8 and
1.8  0.8 at 12 and 24 months, respectively (Figure E1, B).
Echocardiographic Follow-up
Early echocardiography after the procedure documented
an increase in aortic valve area from 0.6  0.2 cm2 preoper-The Journal of Thoracic and Caratively to 1.4  0.3 cm2 at 1 month and a reduction in mean
transaortic pressure gradient from 43.6  16.3 mm Hg
preoperatively to 10.1  3.9 mm Hg at 1 month. The pros-
thetic valve area and transvalvular pressure gradient
remained stable up to 36 months’ follow-up (Figure 4, A
and B). Left ventricular ejection fraction increased slightly
after AVI from a mean of 55.5%  12.6% preoperatively
to 61.2%  7.0% at 24 months (Figure E1, A).
Echocardiography demonstrated that 77.6% of the
patients had paravalvular leak, of whom 46.6% had trivial
leak, 25.9% mild leak, and 5.2% moderate leak after the
procedure. Aortic regurgitation was assessed by a combina-
tion of color Doppler, pressure half-time, vena contracta
width, and flow reversal techniques. The assessment scheme
we have used is similar to that used by Kapur and associ-
ates.18 The degree of aortic regurgitation remained
unchanged and clinically insignificant during follow-up
(Figure E2, A). There was no significant change in mitral
regurgitation during follow-up (Figure E2, B).diovascular Surgery c Volume 139, Number 5 1109
FIGURE 3. Kaplan–Meier survival in 56 patients excluding the first 15
cases. SE, Standard error.
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DDISCUSSION
This report represents the longest follow-up data on trans-
apical transcatheter AVI in a relatively large number of
patients (n¼ 71) being monitored clinically and echocardio-
graphically up to 37 months. We did not exclude our initial
patients despite the significant initial learning curve.
Reported early mortality for septuagenarians and octoge-
narians undergoing primary isolated AVR ranges from
6.6% to 16.7%, whereas reported operative morbidity in-
cluding atrial fibrillation in elderly patients (>70 years old)
after AVR with or without coronary artery bypass was up
to 64% to 76%.19-21 We reviewed 86 patients 80 years of
age or older who underwent isolated AVR between 1998
and 2002 in our University of British Columbia valve data-
base, and the early operative mortality was 5.8% in the co-FIGURE 4. Echocardiographic follow-up. A, Aortic valve area (cm2). B,
Transaortic valve pressure gradient (mm Hg). AVA, Aortic valve area;
MG, mean gradient.
1110 The Journal of Thoracic and Cardiovascular Surhort of patients accepted for conventional AVR
(unpublished data). However, the real risk of conventional
AVR remains unclear in high-risk patients, who often do
not undergo AVR. The predicted operative mortality in the
cohort of our patients was 34.5% 20.4% by logistic Euro-
SCORE and 12.1%  7.7% by STS Risk Calculator. Our
observed 30-day mortality was 33.3% in the first 15 patients
and significantly decreased to 12.5% after the initial learn-
ing curve. Improved teamwork with cumulative experience,
improved apical hemostasis, use of hybrid operating room,
understanding risk factors for potential fatal complications,
and aggressive postoperative care probably contributed to
the decease in early mortality. The observed mortality after
passing the initial learning curve is similar to the STS pre-
dicted operative mortality. However, it should not be con-
cluded that transapical transcatheter AVI might not reduce
operative mortality relative to conventional AVR, inasmuch
as the STS prediction model may underestimate operative
mortality in elderly patients or patients with some specific
comorbidities. The STS prediction model does not reflect
many significant risk factors that were frequently observed
in our patients. These risk factors include end-stage liver dis-
ease, prolonged preoperative hospital stay, general decondi-
tioning, frailty, immobility owing to other medical
conditions, significant abnormalities of other valves, sever-
ity of peripheral vascular and aortic disease, end-stage
lung disease, porcelain aorta, previous chest wall radiation,
and prior infected sternotomy. These conditions contribute
to the early and late mortality and morbidity after transapical
transcatheter AVI, and more so for conventional open heart
AVR.
It is widely documented that average survival of patients
with symptomatic aortic stenosis with symptoms of conges-
tive heart failure is approximately 2 to 3 years. Patients with
aortic stenosis who were accepted for but refused to have
conventional AVR have very poor survival. In a report by
Schwarz and associates,1 144 patients with isolated aortic
stenosis were offered surgery; 125 patients had AVR and
19 patients refused AVR due to personal choice. Survival
at 3 years in the 125 surgically treated patients was 87%,
in contrast to 21% in 19 patients who did not undergo an op-
eration. In a report by Kojodjojo and associates,22 3 groups
of patients 80 years of age or greater were followed up for 3
years to investigate the impact of the patient’s choice to re-
fuse conventional AVR on survival. Survival of patients
who were accepted for AVR but refused surgery was ap-
proximately 40% at 3 years, significantly lower than that
of the group of patients who were accepted and underwent
AVR (approximately 87% at 3 years). The 62 patients
who were declined by surgeons for conventional AVR had
the lowest survival at 1, 2, and 3 years (approximately
50%, 25%, and 10%, respectively). Patients who were de-
clined for surgery in Kojodjojo’s study had a lower predicted
operative risk as compared with our patients who underwentgery c May 2010
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34.5%  20.4% in our patients). Reported 1-year survivals
after transcatheter AVI ranged between 65% and 80%. In
our study 1-, 2-, and 3-year survivals were 71.9% 
5.5%, 66.3%  6.4%, and 58.0%  9.5%, respectively.
The 1-, 2-, and 3-year survivals in the cohort of patients
who survived the first 30 days were better (86.6% 
4.7%, 79.8%  6.4%, and 68.8%  10.9%,
respectively). Survival in our selected high-risk elderly
patients who underwent transapical AVI was much better
than that of the cohort of elderly patients who were declined
conventional AVR in Kojodjojo’s report, consistent with
improved survival in comparison with conservative manage-
ment. The current ongoing randomized PARTNER clinical
trial may provide more definitive information on whether
transapical AVI may improve survival in selected high-
risk patients with aortic stenosis.
Our data has shown that the initial learning curve does
significantly influence early mortality (33.3% in the first
15 patients vs 12.5% in the remainder of the patients), but
does not significantly affect 2-year survival (68.1% 
7.9% in patients excluding the first 15 patients vs 66.3%
 6.4% in all patients). The study has also demonstrated
that late valve-related complications are rare and that there
is no structural valve deterioration or nonstructural valve
dysfunction during follow-up. However, long-term durabil-
ity of the transcatheter tissue valve remains to be determined.
Transapical AVI can provide significant symptomatic
benefit. Themajority of survivors had NYHA class I–II heart
failure symptoms at follow-up. Patients with significant lung
disease generally have less improvement in dyspnea. Most
of the survivors were satisfied with their cardiac condition
and were living independently at follow-up.
Echocardiographic follow-up demonstrated stable func-
tion of the balloon-expandable transcatheter bioprosthetic
valves. Trivial to mild paravalvular regurgitation was
common immediately after deployment of the bioprostheses
but was clinically insignificant and remained stable up to
37 months. A frequent location of trivial to mild paravalvu-
lar leaks is at the posterior portion of the annulus,
where there is relatively less tissue consisting of a thin
layer of the fibrotic aortomitral curtain. More significant
paravalvular leaks are infrequent and most likely result
from incomplete deployment or suboptimal positioning of
bioprostheses. Optimal positioning, correct measurement
of the aortic annular size, and selection of an appropriate
size of a transcatheter valve are the important factors to
reduce the incidence of paravalvular leaks. The mean valve
area of the transcatheter valve was approximately 1.4 to 1.5
cm2 and mean transaortic valve pressure gradient was ap-
proximately 10 mm Hg, remaining stable up to 37 months.
Concomitant severe mitral regurgitation in the presence of
severe aortic stenosis is generally considered an indication
for a combined aortic and mitral valve procedure with anThe Journal of Thoracic and Carattendant increase in operative mortality and morbidity,
particularly in patients with advanced age and significant co-
morbid conditions. In the present series, 36.9% of patients
had grades 3 and 4 mitral regurgitation preoperatively, and
they appeared to tolerate the transapical AVI procedure in-
traoperatively. The mitral regurgitation remained unchanged
or slightly decreased after transapical AVI. This suggests
that a conservative approach to coexisting mitral valve
regurgitation may be a reasonable approach in selected
high-risk patients. Left ventricular systolic function (ejection
fraction) remained stable or improved slightly after transap-
ical AVI.
Immediate device embolization after valve deployment is
a documented complication23 but was not observed in this
cohort undergoing transapical AVI. Theoretically, better
coaxial positioning and stabilization of the device during
deployment can be achieved with the transapical approach
because of a short, straight line from the apex to the annulus,
relative to the transfemoral approach. This complication de-
creases significantly with the clinical experience of sur-
geons, interventional cardiologists, and echocardiographers.
In summary, the initial learning curve with transapical
AVI affects early operative mortality but does not appear
to influence late survival. Our clinical and echocardio-
graphic outcomes suggest the survival benefits of transapical
transcatheter AVI in selected high-risk patients with symp-
tomatic aortic stenosis and the structural and functional sta-
bility of the transcatheter bioprostheses in elderly patients.
The transapical transcatheter AVI is an alternative to con-
ventional AVR in selected high-risk patients with symptom-
atic severe aortic stenosis. The next challenge is to better
identify those with a very poor expected midterm survival
despite successful transcatheter AVI. This could be termed
‘‘a second learning curve.’’ The in vivo long-term durability
of the transcatheter bioprosthesis remains to be determined.
At present, conventional AVR remains the first-line therapy
for symptomatic severe aortic stenosis.References
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Dr Michael J. Mack (Dallas, Tex). My conflict of interest
disclosure is that I am a member of the Partner trial and therefore
I am a consultant to Edwards Lifesciences (Irvine, Calif).
I would like to congratulate the team in Vancouver for their
pioneering efforts, not only Dr Ye but also Drs Anson Cheung
and John Webb. I would like to highlight some of their experience
and ask 4 questions.
Jian, your series comprises 71 patients at a mean follow-up
of 12.9 months. The 30-day mortality is 16.9% with an STS pre-
dicted mortality of 12.5%. Two-year survival is 66% and 3-year
survival is 58%. I think this needs to be put in a context that every-
body needs to understand: this is an integrated program with the1112 The Journal of Thoracic and Cardiovascular Surtransfemoral approach, and this is a ‘‘transfemoral first’’ program
so that the patients in whom the transapical approach was used in
a way are the ‘‘worst of the worst.’’ Not only are they patients
who are in inoperable condition or at very high risk for surgery,
but they are not candidates for the transfemoral approach either.
Thus, in a way you have had to develop this procedure on the pa-
tients in the worst condition.
First question: In the first 15 patients, you have highlighted that
there is a 33% mortality and that that was due to the learning curve.
What have you learned so that the rest of us can avoid that learning
curve? Is it patient selection? Is it specific aspects of the technique?
Is it early-stage technology? What are the specific learning curves
that the rest of us can avoid?
Dr Ye. Thank you very much for your comments. I would like to
make several points to emphasize in avoiding complications and
the learning curve.
1. Patient selection: I think some really ill and elderly patients
with end-stage organ diseases should not be recommended for
this procedure because correcting aortic stenosis would not neces-
sarily reverse their poor outcome.
2. Hybrid operating room with a high-quality imaging system:
We performed our initial cases in our regular operating room
with a portable C-arm fluoroscope that provides suboptimal images
during the procedure. A hybrid operating room with a high-quality
imaging system improves optimal positioning of transcatheter
valves and success rate of the procedure.
3. Surgical technique: Surgical technique is particularly impor-
tant in avoiding fatal complications, such asmassive apical bleeding.
4. Performers’ experience and knowledge and team work:
Performers should understand potential major complications and
appropriate ways to deal with these complications on an emergency
basis.
5. Postoperative care: These are really sick patients and the
postoperative care is extremely important, especially in preventing
and managing pneumonia, line infection, sepsis, or acute renal fail-
ure. In this cohort of patients, infection, particularly pneumonia,
frequently contributes to poor outcomes. Prevention of deep vein
thrombosis and pulmonary embolism is particularly important in
these elderly patients because they are frequently immobile.
DrMack. Second question: This is a transfemoral first program.
What percent of the transcatheter valves are performed by a transfe-
moral approach and what percent by a transapical one? As the trans-
femoral delivery systems get smaller, more steerable, with more
low-profile nose cones, what do you see as the ultimate role of
the transapical approach?
Dr Ye. Great questions. At our centers, approximately two
thirds and one third of accepted patients for transcatheter AVI un-
derwent the transfemoral and transapical approaches, respec-
tively. At this point, there is no evidence to suggest one
approach is better than another approach. Continuing improve-
ment in the transfemoral delivery systems might change the
role of the transapical approach. However, I believe both ap-
proaches will be advanced simultaneously as each approach has
its own advantages and disadvantages. At present, the transapical
approach is usually performed by thoracic surgeons and the trans-
femoral mainly by cardiologists. Inasmuch as I am a cardiac sur-
geon, it may be biased for me to answer your question. I believe
that the transapical approach will continue to play an importantgery c May 2010
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tages compared with the transfemoral approach: (1) a shorter
and straight route to approach heart valves, which provides better
stabilization, coaxial alignment, and positioning relative to the
transfemoral approach; (2) a better way for aortic valve implanta-
tion in patients with previous mitral valve replacement because
stabilization is more important in these patients given high risks
of displacement of the balloon during valve deployment (inflating
balloon against a strut of mitral prosthesis); (3) an optimal ap-
proach for aortic valve-in-valve implantation into failed biopros-
theses; and (4) an optimal approach to access the mitral valve.
We have performed more than 10 cases of transapical valve-in-
valve implantation into failed bioprostheses at the mitral, aortic,
and the tricuspid positions. At present, the transapical approach
is the only way for valve-in-valve implantation. Therefore, I be-
lieve the transapical will continue to play a major role in this
evolving transcatheter technology. There is no randomized trial
to compare the transfemoral and transapical approaches at this
time, and the patient populations in the transapical and transfe-
moral groups are quite different, as Dr Mack mentioned. At
this point, no one is able to claim that transfemoral is better
than transapical because the populations in these 2 groups are
very different. I think a randomized controlled clinical trial toThe Journal of Thoracic and Carcompare surgery, transfemoral, and transapical approaches is
necessary.
Dr Mack. If you had to start a transcatheter valve program all
over again knowing what you know right now, would it be a trans-
apical first or transfemoral first? Second, if you had an elderly
relative, 90 years old, STS risk of 10, would you recommend con-
ventional surgery, transapical, or transfemoral?
Dr Ye. Those are excellent questions. I think the transapical
approach is pretty safe. More important, it provides a better posi-
tioning and stabilization during valve implantation. To start a pro-
gram, I think there is no reason that we cannot start the transapical
first. With development of apical closure devices, the transapical
could become a better approach.
Regarding the second part of your question on the therapeutic
option for a 90-year-old patient with aortic stenosis, I think it is dif-
ficult to give a definite answer at this moment because no random-
ized trial has been performed to compare surgical, transfemoral,
and transapical. Personally, I would not make a recommendation
just based on the age and STS score, without my assessment of
the patient. Generally speaking, for a patient 90 years old or great-
er, I would recommend either the transapical or transfemoral ap-
proach unless the patient is in very good condition with limited
comorbidities.diovascular Surgery c Volume 139, Number 5 1113
FIGURE E1. Echocardiographic and clinical follow-up. Left ventricular
ejection fraction (LVEF %) (A), and New York Heart Association
(NYHA) functional class (1-4) (B). ns, Not significant.
FIGURE E2. Echocardiographic follow-up: aortic regurgitation (AR)
(1¼ trivial, 2¼mild, 3¼moderate, 4¼ severe) (A) and mitral regurgitation
(MR) (1 ¼ trivial, 2¼ mild, 3 ¼ moderate, 4¼ severe) (B).
Table E1. Baseline characteristics of 71 patients
Characteristics No. of patients Percentage
Age (80.0  8.1 y)*
 90 y 6 8.5
80–89 y 36 50.7
Female sex 44 62.0
Hypertension 64 90.1
Diabetes 20 28.2
Coronary artery disease 53 74.6
Prior myocardial infarction 50 70.4
Severe lung disease 20 28.2
Prior coronary artery bypass grafting 31 43.7
History of cerebral ischemic event 22 31.0
Peripheral vascular disease 61 85.9
History of gastrointestinal bleeding 12 16.9
Estimated glomerular filtration
rate<60 mL/min
41 57.7
Ejection fraction<50% 18 26.5
Pulmonary hypertension
Systolic pressure  60 mm Hg 15 21.1
Systolic pressure 50–59 mm Hg 6 8.6
Systolic pressure 40–49 mm Hg 21 30.0
Porcelain aorta 15 21.1
History of smoking 49 69
Atrial fibrillation 24 33.8
Permanent pacemaker 13 18.3
Preoperative hemoglobin<120 mg/L 33 46.5
*Mean  standard deviation.
Acquired Cardiovascular Disease Ye et al
1113.e1 The Journal of Thoracic and Cardiovascular Surgery c May 2010
A
C
D
